Bruning P F, Bonfrer J M, Hart A A, de Jong-Bakker M, Linders D, van Loon J, Nooyen W J
Department of Clinical Oncology, The Netherlands Cancer Institute, Amsterdam.
Br J Cancer. 1988 Oct;58(4):497-9. doi: 10.1038/bjc.1988.248.
The influence of tamoxifen on plasma lipids and lipoproteins was monitored in 46 postmenopausal and 8 premenopausal women treated for advanced breast cancer up till 6 months. Total cholesterol (total-C) did not significantly change. However, high density lipoprotein cholesterol (HDL-C) and the HDL-C/total-C ratio rose significantly. Low density lipoprotein cholesterol was significantly decreased. Triglycerides and free fatty acids did not change markedly. The concomitant rise of sex hormone binding globulin and thyroxine binding globulin indicates that the increase of HDL-C with prolonged use of tamoxifen is compatible with an intrinsic oestrogenic effect of tamoxifen on the liver. The increased HDL-C/total-C ratio lends no support to the concern that long-term administration of this anti-oestrogenic drug might lead to an increased cardiovascular risk.
对46名绝经后和8名绝经前晚期乳腺癌患者进行了长达6个月的他莫昔芬治疗,并监测其对血浆脂质和脂蛋白的影响。总胆固醇(总胆固醇)无显著变化。然而,高密度脂蛋白胆固醇(HDL-C)和HDL-C/总胆固醇比值显著升高。低密度脂蛋白胆固醇显著降低。甘油三酯和游离脂肪酸无明显变化。性激素结合球蛋白和甲状腺素结合球蛋白同时升高表明,长期使用他莫昔芬导致HDL-C升高与他莫昔芬对肝脏的内在雌激素样作用相符。HDL-C/总胆固醇比值升高并不支持长期使用这种抗雌激素药物可能导致心血管风险增加的担忧。